Novartis’ $2B Takeover of Endocyte, Revolution-Warp Drive, & Amgen’s Foray in DNA Sequencing

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

House Dems Hunt Pharma Big Game, Shutdown Ripples, & JPM Reflections
Lilly Buys Loxo, Baselga Resurfaces, and Bluebird’s Gene Therapy Payment Plan
Genentech & Adaptive’s TCR Strategy, Arch’s New Cell Therapy Co, & Esperion’s Rich EU Deal
BMS-Celgene MegaMerger, Verily Pockets $1B, and AbbVie’s Wager on CD39